PT - JOURNAL ARTICLE AU - Sunae Ryu AU - Woo Jin Jung AU - Zheng Jiao AU - Jung-Woo Chae AU - Hwi-yeol Yun TI - External validation of the predictive performance of population pharmacokinetic models for phenobarbital in pediatric patients AID - 10.1101/2020.09.10.20192005 DP - 2020 Jan 01 TA - medRxiv PG - 2020.09.10.20192005 4099 - http://medrxiv.org/content/early/2020/09/11/2020.09.10.20192005.short 4100 - http://medrxiv.org/content/early/2020/09/11/2020.09.10.20192005.full AB - Aim Several studies have reported population pharmacokinetic models for phenobarbital (PB), but the predictive performance of these models has not been well documented. This study aims to do external validation of the predictive performance in published pharmacokinetic models.Methods Therapeutic drug monitoring data collected in neonates and young infants treated with PB for seizure control, was used for external validation. A literature review was conducted through PubMed to identify population pharmacokinetic models. Prediction- and simulation-based diagnostics, and Bayesian forecasting were performed for external validation. The incorporation of size or maturity functions into the published models was also tested for prediction improvement.Results A total of 79 serum concentrations from 28 subjects were included in the external validation dataset. Seven population pharmacokinetic studies of PB were selected for evaluation. The model by Voller et al. [27] showed the best performance concerning prediction-based evaluation. In simulation-based analyses, the normalized prediction distribution error of two models (those of Shellhaas et al. [24] and Marsot et al. [25]) obeyed a normal distribution. Bayesian forecasting with more than one observation improved predictive capability. Incorporation of both allometric size scaling and maturation function generally enhanced the predictive performance, but with marked improvement for the adult pharmacokinetic model.Conclusion The predictive performance of published pharmacokinetic models of PB was diverse, and validation may be necessary to extrapolate to different clinical settings. Our findings suggest that Bayesian forecasting improves the predictive capability of individual concentrations for pediatrics.What is already known about this subjectPharmacokinetics of phenobarbital (PB) have been reported large inter-individual difference and treatment with PB required therapeutic drug monitoring.Population pharmacokinetic models for PB have been studied by several researchers but predictive performance of these models has not been well documented.What this study addsPredictive performance of pharmacokinetic models of phenobarbital (PB) was various and required validation for extrapolation to different clinical settings.Bayesian forecasting could improve the predictability for individual drug concentrations.Imputation of both size and maturation functions could help to enhance the predictability of pharmacokinetic models for pediatric patients.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis study was done with CPC(clinical pharmacokinetic consult) data in hospitalFunding StatementThis study was supported by research funds from Chungnam National University and also supported by Institute of Information & communications Technology Planning & Evaluation (IITP) grant funded by the Korea government (MSIT) (No.2020-0-01441, Artificial Intelligence Convergence Research Center (Chungnam National University))Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Approval for this study was provided by the institutional ethics committee of Kyunghee University HospitalAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author upon reasonable request.